Enterprise Value
345.9B
Cash
5.619B
Avg Qtr Burn
N/A
Short % of Float
0.97%
Insider Ownership
0.05%
Institutional Own.
78.75%
Qtr Updated
03/31/24
Drug Pipeline
Powered by
![](/BPIQ_Pill.png)
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
KEYTRUDA Details Solid tumor/s, Non-small cell lung carcinoma, Cancer | Approved Update | |
PADCEV® (enfortumab vedotin-ejfv) + KEYTRUDA® (pembrolizumab) Details Solid tumor/s, Cancer, Urothelial cancer | Approved Update | |
GARDASIL 9 Details Human Papillomavirus 9-valent Vaccine, Human papillomavirus | Approved Update | |
M-M-R®II, VARIVAX®, and ProQuad® Details Vaccine, Viral infection | Approved Update | |
KEYTRUDA+ Padcev (enfortumab vedotin) Details Cancer, Urothelial carcinoma | Approved Quarterly sales | |
KEYTRUDA in comb w/chemotherapy Details Non-small cell lung carcinoma, Solid tumor/s, Cancer | Approved Quarterly sales | |
KEYTRUDA+ chemotherapy Details Cancer, Biliary Tract Cancer | Approved Quarterly sales | |
WELIREG® (belzutifan) Details Renal cell carcinoma | Approved Quarterly sales | |
WINREVAIR (sotatercept-csrk) Details Pulmonary arterial hypertension | Approved Quarterly sales | |
PREVYMIS™ (letermovir) Details Cytomegalovirus, Viral infection | Approved Quarterly sales | |
CAPVAXIVE (V116) Details Pneumococcal Conjugate Vaccine | Approved Quarterly sales | |
KEYTRUDA +carboplatin + paclitaxel Details Cancer, Solid tumor/s, Carcinoma , Endometrial cancer | Approved Quarterly sales | |
LYNPARZA(olaparib) + abi/pred Details Solid tumor/s, Cancer, Castration-resistant prostate cancer | Approved Quarterly sales | |
ERVEBO Details Ebola | Approved Quarterly sales | |
KEYTRUDA + chemotherapy Details Cancer, Gastroesophageal adenocarcinomas, Gastric cancer | Approved Quarterly sales | |
KEYTRUDA in comb w/ EBRT + brachytherapy Details Cervical cancer, Cancer | Approved Quarterly sales | |
TUKYSA (Tucatinib) Details Solid tumor/s, Colorectal cancer , Cancer, Metastatic colorectal cancer | Approved Quarterly sales | |
KEYTRUDA+ trastuzumab+ chemotherapy Details Cancer, Gastroesophageal adenocarcinomas, Gastric cancer | Approved Quarterly sales | |
KEYTRUDA+ chemotherapy Details Cancer, Mesothelioma, Malignant pleural/peritoneal mesothelioma | PDUFA Approval decision | |
Patritumab deruxtecan (HER3-DXd) Details Non-small cell lung carcinoma | BLA Resubmission | |
Gefapixant (MK-7264) Details Chronic cough | NDA FDA meeting | |
Islatravir+ Doravirine Details Viral infection, Human immunodeficiency virus | Phase 3 Data readout | |
Bomedemstat Details Thrombocythemia | Phase 3 Data readout | |
MK-2870 Details Non-small cell lung carcinoma, Cancer | Phase 3 Data readout | |
Nemtabrutinib Details Cancer, Small lymphocytic lymphoma , Chronic lymphocytic leukemia | Phase 3 Data readout | |
MK-0616 Details Cardiovascular disease , Hypercholesterolemia | Phase 3 Data readout | |
MK-1084 +KEYTRUDA® Details Non-small cell lung carcinoma, Cancer | Phase 3 Data readout | |
MK-5684 (ODM-208) Details Cancer, Castration-resistant prostate cancer | Phase 3 Data readout | |
LAGEVRIO™ (molnupiravir) Details Viral infection, COVID-19 | Phase 3 Data readout | |
KEYTRUDA+pemetrexed Details Solid tumor/s, Non-small cell lung carcinoma, Cancer | Phase 3 Data readout | |
KEYTRUDA Details Solid tumor/s, Cancer, Triple-negative breast cancer , Breast cancer | Phase 3 Update | |
KEYTRUDA Details Cancer, Renal cell carcinoma | Phase 3 Update | |
KEYTRUDA® (pembrolizumab)+ LYNPARZA® (olaparib) Details Cancer, Non-small cell lung carcinoma | Phase 3 Update | |
KEYTRUDA + LENVIMA Details Cancer, Renal cell carcinoma | Phase 3 Update | |
KEYTRUDA +LENVIMA® (lenvatinib) Details Cancer, Carcinoma , Endometrial cancer | Phase 3 Update | |
KEYTRUDA Details Cancer, Solid tumor/s, ER+/HER2- breast cancer | Phase 3 Update | |
KEYTRUDA Details Cancer, Solid tumor/s, Urothelial carcinoma | Phase 3 Update | |
KEYTRUDA +LENVIMA® (lenvatinib) Details Cancer, Non-small cell lung carcinoma | Phase 3 Update | |
MK-0616 Details Hypercholesterolemia | Phase 3 Initiation | |
PRA023 (Anti-TL1A mAb) Details Crohns disease | Phase 3 Initiation | |
Raludotatug Deruxtecan Details Platinum-resistant ovarian cancer, Cancer | Phase 2/3 Data readout | |
Efinopegdutide (MK-6024) Details Non-Alcoholic Fatty Liver Disease, Liver disease | Phase 2b Initiation | |
Bomedemstat Details Myelofibrosis | Phase 2 Data readout | |
MK-7240 (PRA023) (Anti-TL1A mAb) Details Irritable bowel syndrome, Crohns disease, Ulcerative colitis | Phase 2 Update | |
PRA023 (Anti-TL1A mAb) Details Systemic sclerosis, Autoimmune disease | Phase 2 Update | |
PRA023 (Anti-TL1A mAb) Details Autoimmune disease, Systemic sclerosis | Phase 2 Update | |
Belzutifan + cabozantinib Details Cancer, Renal cell carcinoma | Phase 2 Update | |
HPN328 (DLL3) +/- atezolizumab Details Cancer, Small cell lung cancer, Solid tumor/s | Phase 1/2 Update | |
HPN217 (BCMA) Details Multiple myeloma | Phase 1 Update | |
PRA052 Details Inflammatory bowel disease | Phase 1 Update | |
KEYTRUDA + LENVIMA Details Cancer, Head and neck squamous cell carcinoma | Failed Discontinued | |
KEYTRUDA+ enzalutamide + androgen deprivation therapy (ADT) Details Solid tumor/s, Cancer, Castration-resistant prostate cancer | Failed Discontinued |